Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062366 | 1.00 | PIM1 (0.39) | PIM1KDRIRAK4P2RX3SLC6A2 | |
| SCHEMBL4756377 | 1.00 | PIM1 (0.39) | PIM1KDRIRAK4P2RX3SLC6A2 | |
| Hydrochloric Acid SCHEMBL629946 | 0.99 | PIM1 (0.39) | PIM1KDRIRAK4P2RX3SLC6A2 | |
| Hydrochloric Acid SCHEMBL3360571 | 0.99 | PIM1 (0.39) | PIM1KDRIRAK4P2RX3SLC6A2 | |
| SCHEMBL1243396 | 0.85 | LMNA (0.40) | PIM1KDRIRAK4P2RX3 | |
| SCHEMBL13433702 | 0.85 | PIM1 (0.39) | PIM1KDRIRAK4P2RX3CHEK2 | |
| Hydrochloric Acid SCHEMBL3359714 | 0.84 | PIM1 (0.39) | PIM1KDRIRAK4P2RX3CHEK2 | |
| SCHEMBL8229174 | 0.84 | IRAK4 (0.39) | PIM1IRAK4 | |
| Hydrochloric Acid SCHEMBL2430460 | 0.83 | IRAK4 (0.39) | PIM1IRAK4 | |
| SCHEMBL10082568 | 0.81 | TYMS (0.32) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694086-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-9694086-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-07-04 | — | — | US | disclosed |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-25 | — | — | US | disclosed |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-25 | — | — | US | disclosed |
| US-20160235805-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-18 | — | — | US | disclosed |
| US-20160235805-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-08-18 | — | — | US | disclosed |
| US-9163061-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163061-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2041159-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-09-28 | — | — | EP | disclosed |
| WO-2011002807-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009082697-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2007148135-A1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235805-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | PIM1 2402/4885KDR 4661/4885IRAK4 2598/4885 |
| US-20100069294-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | PIM1 2402/4885KDR 4661/4885IRAK4 2598/4885 |
| US-20130131105-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | PIM1 2402/4885KDR 4661/4885IRAK4 2598/4885 |
| US-20160243249-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | PIM1 2402/4885KDR 4661/4885IRAK4 2598/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | PIM1 2402/4885KDR 4661/4885IRAK4 2598/4885 |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | PIM1 1222/4885KDR 1510/4885IRAK4 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.